A prospective, randomized, double-blind, double-dummy, placebo and celecoxib (200 mg/day)-controlled trial concluded that a 800 mg/day pharmaceutical-grade Chondroitin sulfate (CS) is superior to placebo and similar to celecoxib in reducing pain and improving function over 6 months in symptomatic knee osteoarthritis (OA) patients. The trial included 604 patients of knee osteoarthritis in five European countries and followed for 182 days. CS and celecoxib showed a greater significant reduction in pain on a Visual Analogue Scale (VAS) and in the Lequesne Index (LI, which combines pain and function) than placebo. In the intention-to-treat population, pain reduction in VAS at day 182 in the CS group (−42.6 mm) and in celecoxib group (−39.5 mm) was significantly greater than the placebo group (−33.3 mm). Similar trend for the LI, as reduction in this metric in the CS group (−4.7) and celecoxib group (−4.6) was significantly greater than the placebo group (−3.7). No difference in VAS and LI was observed between CS and celecoxib. All treatments demonstrated excellent safety profiles. The CS tablets contained highly purified chondroitin 4 & 6 sulfate in a concentration not less than 95%. The study confirmed the efficacy and safety of chondroitin. Source: http://ard.bmj.com/
Both clinician-rated and patient-reported outcomes suggested that mindfulness-based stress reduction (MBSR) was well-tolerated with comparable…
The number of individuals with high blood pressure (BP) is increasing worldwide. The trajectory of…
A single combined measure of high-sensitivity C-reactive protein (CRP), low-density lipoprotein (LDL) cholesterol, and lipoprotein(a)…
A French multicenter, open label, randomized, noninferiority trial suggested that interruption of long-term beta-blocker treatment…
A US prospective cohort study demonstrated that replacement of animal fat with an equivalent amount…
An ongoing UK national prospective program shows remission of type 2 diabetes (T2D) outside of…
This website uses cookies.